2019
DOI: 10.26452/ijrps.v10i2.395
|View full text |Cite
|
Sign up to set email alerts
|

Absorption enhancement effect of piperine and chitosan on ganciclovir sol-id lipid nanoparticles: formulation, optimization and invivo pharmacoki-netics

Abstract: The purpose of the present study was to formulate Solid Lipid Nanoparticles (SLNs) of Ganciclovir (GCV) in combination with Chitosan and Piperine for absorption enhancement effect. GCV loaded SLNs were prepared by hot homogenization method, optimized and characterized. Formulated SLNs were incorporated with absorption enhancers and characterized for invitro absorption (with chicken intestine), histopathological and invivo pharmacokinetic studies. Invitro absorption studies revealed that the permeability coeffi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 18 publications
0
1
0
Order By: Relevance
“…Regarding antiviral formulations intended for systemic effect after oral administration (Gaur et al, 2014;Shi et al, 2015;Ravindra Babu et al, 2019), an interesting work by Ravi et al (2014) evaluated the comparative performance of the protease inhibitor lopinavir (LPV)-SLN with respect to LPV alone and the combination of LPV-Ritonavir (RTV). LPV is co-formulated with subtherapeutic doses of Ritonavir to overcome its poor oral BA due to CYP3A4 metabolism and P-glycoprotein (P-gp) efflux, both inhibited by RTV.…”
Section: A Descriptive Analysis Of Therapeutic Application Fields Of Slnmentioning
confidence: 99%
“…Regarding antiviral formulations intended for systemic effect after oral administration (Gaur et al, 2014;Shi et al, 2015;Ravindra Babu et al, 2019), an interesting work by Ravi et al (2014) evaluated the comparative performance of the protease inhibitor lopinavir (LPV)-SLN with respect to LPV alone and the combination of LPV-Ritonavir (RTV). LPV is co-formulated with subtherapeutic doses of Ritonavir to overcome its poor oral BA due to CYP3A4 metabolism and P-glycoprotein (P-gp) efflux, both inhibited by RTV.…”
Section: A Descriptive Analysis Of Therapeutic Application Fields Of Slnmentioning
confidence: 99%